The drug "Strofantin" refers to the group of cardiac glycosides. It is recommended for heart failure characterized by acute or chronic form, as well as with paroxysmal tachycardia.
Medicinal product "Strofantin", formthe release of which is a sterile solution, in its physico-chemical properties is a clear liquid that has no color. The main active substance of the drug is a mixture of cardiac glycosides, obtained from the seeds of the medicinal plant strophant.
Drug "Strofantin", instructionon the application of which acquaints with its action, produces a cardiotonic effect, increasing the speed and force of contraction of the heart muscle. Glycosides, included in the composition of the drug, contribute to an increase in the volume of blood ejected by the myocardium for one reduction and within a minute. With heart failure, the drug increases the emptying of the ventricles. This reduces the size of the myocardium, which reduces its need for oxygen. The therapeutic effect of the drug manifests itself within three to ten minutes after its introduction and lasts one to three days.
Drug "Strofantin", instructionon the application of which describes its effect on the body, has all the basic pharmacological properties that cardiac glycosides possess, however, unlike them, the cardiotonic action of the drug is stronger and manifests itself quite quickly. The medication affects the rhythm of the myocardium insignificantly and does not interfere with the impulses in the bundle. The drug "Strofantin", the instruction to which describes the method of its use, is administered intravenously, in small doses. Due to its instability, it exhibits little therapeutic effect when taken orally. The drug does not accumulate in the body, however, it can cause a toxic reaction when interacting with digitalis medicaments. To avoid this effect, intravenous injection is performed only after the course of treatment with digitalis means. The break should be from four to six days. Almost forty percent of the injected drug binds to proteins that are in the blood plasma. The main active substances are excreted through the kidneys in an unchanged form.
Drug "Strofantin" (instructionon the application describes the main pathologies in which it is recommended to use it) is indicated for heart failure of the second and third stage, which is chronic, myocardial rhythm disturbances, supraventricular tachycardia, and atrial fibrillation.
May cause drug and adverse side effectseffects on the body. In most cases, they are manifested in overdose, accelerated intravenous administration, as well as with increased individual sensitivity of the patient to glycosides. Possible violations of heart rhythm and conduction of the myocardium. Diarrhea, vomiting and nausea are also possible, and in especially severe pathologies - mesenteric infarction. Malfunctions in the work of the sensory organs and the central nervous system can result in the appearance of headaches, depressions, hallucinations, psychoses, insomnia and visual impairments. In some cases, men may develop gynecomastia. There is also the possibility of allergic reactions.
Drug "Strofantin", instructionthe use of which warns against contraindications, is not prescribed for acute myocardial infarction, glycosidic intoxication, ventricular tachycardia, pronounced bradycardia, hypercalcemia and hypokalemia, weakness syndrome of the sinus node, aneurysm of the thoracic aorta, and atrioventricular blockade in the second and third degree.
